Bronno van der Holt

17.3k citations

224 papers · 7.8k indexed · h-index 51

Co-authors: Pieter Sonneveld Jan J. Cornelissen Bob Löwenberg Leo F. Verdonck Martin J. van den Bent Joost W. J. van Esser Henk M. Lokhorst Jan W. Gratama
Topics: Multiple Myeloma Research and Treatments (68 papers)Cancer Treatment and Pharmacology (32 papers)Protein Degradation and Inhibitors (30 papers)
Cited by: Hematology Oncology Genetics
Journals: The Lancet Journal of Clinical Oncology Blood
Partner nations: Netherlands United States Belgium

In The Last Decade

Bronno van der Holt

211 papers receiving 7.7k citations

Peers

Countries citing papers authored by Bronno van der Holt

Since Specialization

Citations

This map shows the geographic impact of Bronno van der Holt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bronno van der Holt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bronno van der Holt more than expected).

Fields of papers citing papers by Bronno van der Holt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bronno van der Holt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bronno van der Holt. The network helps show where Bronno van der Holt may publish in the future.

Co-authorship network of co-authors of Bronno van der Holt

This figure shows the co-authorship network connecting the top 25 collaborators of Bronno van der Holt. A scholar is included among the top collaborators of Bronno van der Holt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bronno van der Holt. Bronno van der Holt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling 2024 ·Cancer Medicine ·(unknown),Yvette van Norden,Jurjen Versluis,Anita W. Rijneveld,Bronno van der Holt,Okke de Weerdt,Bart J. Biemond,Arjan A. van de Loosdrecht,(unknown),Mar Bellido,Michel van Gelder,Walter J. F. M. van der Velden,Dominik Selleslag,(unknown),Vincent H. J. van der Velden,Liesbeth C. de Wreede,Douwe Postmus,Francesco Pignatti,Jan J. Cornelissen	2
2	Music to prevent deliriUm during neuroSurgerY (MUSYC): a single-centre, prospective randomised controlled trial 2023 ·BMJ Open ·(unknown),(unknown),J Jeekel,Clemens M.F. Dirven,Steven A. Kushner,(unknown),Michiel Coesmans,Marten J. Poley,Mathijs S. van Schie,Bronno van der Holt,Markus Klimek,Arnaud J.P.E. Vincent	11
3	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile 2022 ·Journal of Clinical Oncology ·Davine Hofste op Bruinink,Rowan Kuiper,Mark van Duin,Tom Cupedo,Vincent H. J. van der Velden,Remco M. Hoogenboezem,Bronno van der Holt,H. Berna Beverloo,(unknown),(unknown),Francesca Gay,Annemiek Broijl,Hervé Avet‐Loiseau,Nikhil C. Munshi,Pellegrino Musto,Philippe Moreau,Sonja Zweegman,Niels W.C.J. van de Donk,Pieter Sonneveld	16
4	Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence 2022 ·Leukemia ·Kristine Misund,Davine Hofste op Bruinink,Eivind Coward,Remco M. Hoogenboezem,Even H Rustad,Mathijs A. Sanders,Morten Beck Rye,Anne‐Marit Sponaas,Bronno van der Holt,Sonja Zweegman,Eivind Hovig,Leonardo A. Meza‐Zepeda,Anders Sundan,Ola Myklebost,Pieter Sonneveld,Anders Waage	34
5	V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma 2021 ·Cancers ·Pim Mutsaers,Hayri E. Balcıoğlu,Rowan Kuiper,Dora Hammerl,Rebecca Wijers,Mark van Duin,Bronno van der Holt,Annemiek Broijl,Walter A. Gregory,Sonja Zweegman,Pieter Sonneveld,Reno Debets	12
6	Exploratory Study of Predicted Indirectly ReCognizable HLA Epitopes in Mismatched Hematopoietic Cell Transplantations 2019 ·Frontiers in Immunology ·Kirsten Geneugelijk,(unknown),Hanneke W. M. van Deutekom,Jorg J. A. Calis,(unknown),Can Keşmir,Machteld Oudshoorn,Bronno van der Holt,Ellen Meijer,Sacha Zeerleder,Marco R. de Groot,Peter A. von dem Borne,Nicolaas Schaap,Jan J. Cornelissen,Jürgen Kuball,Eric Spierings	14
7	Lack of detectable platelet autoantibodies is correlated with nonresponsiveness to rituximab treatment in ITP patients 2017 ·Blood ·Leendert Porcelijn,Elly Huiskes,Martin R. Schipperus,Bronno van der Holt,Masja de Haas,Jaap Jan Zwaginga	30
8	Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human 2017 ·Clinical Cancer Research ·Joachim G.J.V. Aerts,Pauline L. de Goeje,Robin Cornelissen,Margaretha E.H. Kaijen-Lambers,Koen Bezemer,Cor H. van der Leest,Niken M. Mahaweni,André Kunert,Ferry A.L.M. Eskens,Cynthia Waasdorp,Eric Braakman,Bronno van der Holt,Arnold G. Vulto,Rudi W. Hendriks,Joost P. Hegmans,Henk C. Hoogsteden	71
9	Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial 2017 ·University of Southern Denmark Research Portal (University of Southern Denmark) ·Sonja Zweegman,Pieter Sonneveld,Bronno van der Holt,Anders Waage,Saskia K. Klein,Niels Abildgaard,(unknown),Markus Hansson,Fredrik Schjesvold,Mark‐David Levin,Claudia A.M. Stege,(unknown),(unknown),Annemiek Broyl,(unknown),(unknown),Ellen van der Spek,(unknown),Sónia M. P. R. M. Cunha,Einar Haukås	0
10	Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology 2015 ·Haematologica ·Bouke P. C. Hazenberg,Alexandra Croockewit,Bronno van der Holt,Sonja Zweegman,Gerard M.J. Bos,(unknown),Reinier Raymakers,(unknown),Edo Vellenga,P. Wijermans,Peter A. von dem Borne,M. H. van Oers,Okke de Weerdt,(unknown),H M Lokhorst,(unknown)	16
11	CYP3A422* Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity 2013 ·Clinical Cancer Research ·Anne‐Joy M. de Graan,Laure Elens,Jason A. Sprowl,Alex Sparreboom,Lena E. Friberg,Bronno van der Holt,Pleun J. de Raaf,Peter de Bruijn,Frederike K. Engels,Ferry A.L.M. Eskens,Erik A.C. Wiemer,Jaap Verweij,Ron H.J. Mathijssen,Ron H. N. van Schaik	91
12	Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy 2012 ·Clinical Cancer Research ·Anne‐Joy M. de Graan,Walter J. Loos,Lena E. Friberg,Sharyn D. Baker,Jessica M. van der Bol,Leni van Doorn,Erik A.C. Wiemer,Bronno van der Holt,Jaap Verweij,Ron H.J. Mathijssen	29
13	Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial 2011 ·Blood ·(unknown),Bronno van der Holt,Marie José Kersten,Sonja Zweegman,Ellen Meijer,Gerwin Huls,Jan J. Cornelissen,Jeroen J. W. M. Janssen,Cynthia Huisman,(unknown),(unknown),Maarten E. Emmelot,Pieter Sonneveld,Henk M. Lokhorst,Tuna Mutis,Monique C. Minnema	139
14	High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study 2010 ·Blood ·Eduard J. Libourel,Pieter Sonneveld,Bronno van der Holt,Moniek P.M. de Maat,Frank W.G. Leebeek	61
15	Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison 2008 ·Blood ·Jan J. Cornelissen,Bronno van der Holt,Gregor Verhoef,Mars B. van ’t Veer,Marinus H. J. van Oers,Harry C. Schouten,Gert J. Ossenkoppele,Pieter Sonneveld,Johan Maertens,Marinus van Marwijk Kooy,M Schaafsma,Pierre W. Wijermans,Douwe H. Biesma,Shulamit Wittebol,P.J. Voogt,Joke W. Baars,Pierre Zachée,Leo F. Verdonck,Bob Löwenberg,A. W. Dekker	121
16	Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. 2004 ·PubMed ·Jeanette K. Doorduijn,(unknown),Bronno van der Holt,Michel van Agthoven,Pieter Sonneveld,Carin A. Uyl‐de Groot	23
17	Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients 2003 ·Brain ·Setareh Shamsili,(unknown),B. de Leeuw,Martin J. van den Bent,Herbert Hooijkaas,Bronno van der Holt,Charles J. Vecht,Peter Sillevis Smitt	359
18	Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML 2002 ·Blood ·G. J. Ossenkoppele,Wilfried J. Graveland,Pieter Sonneveld,(unknown),Douwe H. Biesma,(unknown),M Schaafsma,Petra H.M. Westveer,Georg Peters,Paul Noordhuis,Petra Muus,Dominik Selleslag,Bronno van der Holt,Michel Delforge,Bob Löwenberg,Gregor Verhoef	2
19	A randomized study on the value of Fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. A report from the Dutch-Belgian hemato-oncology cooperative group (HOVON) 2001 ·Blood ·GJ Ossenkoppele,Bronno van der Holt,Pieter Sonneveld,Edo Vellenga,(unknown),Douwe H. Biesma,Petra H.M. Westveer,Georg Peters,Paul Noordhuis,Petra Muus,Wilfried J. Graveland,M Schaafsma,Dominik Selleslag,Michel Delforge,Bob Löwenberg,Gregor Verhoef	2
20	A randomized study of granulocyte-colony stimulating factor applied during and after chemotherapy in patients, with poor risk myelodysplastic syndromes: A final report from the Hovon Cooperative Group. 1998 ·Data Archiving and Networked Services (DANS) ·GJ Ossenkoppele,Bronno van der Holt,(unknown),(unknown),LF Verdonck,Pieter Sonneveld,P. W. Wijermans,J. van der Lelie,WLJ van Putten,Bob Löwenberg	1

About Bronno van der Holt

Bronno van der Holt is a scholar working on Hematology, Genetics and Oncology, having authored 224 papers that have together received 7.8k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (68 papers), Cancer Treatment and Pharmacology (32 papers) and Protein Degradation and Inhibitors (30 papers). The work is most often cited by research in Hematology (3.1k citations), Oncology (3.0k citations) and Genetics (990 citations). Bronno van der Holt has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Pieter Sonneveld, Jan J. Cornelissen, Bob Löwenberg, Leo F. Verdonck, Martin J. van den Bent, Joost W. J. van Esser, Henk M. Lokhorst, Jan W. Gratama, Peter Sillevis Smitt and Hartmut Goldschmidt. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact